Home › Research › Risk genes beyond APOE
ADAM10 as a biomarker for Alzheimer's disease: A systematic review
Oliveira Monteiro E Pereira de Almeida MP, Valle Pedroso R, Mantellatto Grigoli M, Vicente Silva T, Manzine PR, Cominetti MR.. Revue neurologique, 2023-07-16
Topic: Amyloid, tau and blood-test diagnosis
Background Studies have shown that A Disintegrin and Metalloproteinase 10 (ADAM10) is the main α-secretase in the non-amyloidogenic cleavage of the amyloid precursor protein (APP), avoiding the production of amyloid-β peptide (Aβ), one of the pathological hallmarks of Alzheimer's disease (AD). Objective To investigate ADAM10 from cerebrospinal fluid (CSF) and plasma/serum as a potential biomarker for AD. Methods A systematic review was carried out in the MEDLINE/PubMed, Web of Science, Embase, and Scopus databases using the terms and Boolean operators: "Alzheimer" AND "ADAM10" AND "biomarker". Citation searching was also adopted. The inclusion criteria were original studies of ADAM10 in blood or CSF in patients with AD. The risk of bias was assessed using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. The analysis methods were registered in the PROSPERO database (#CRD42021274239). Results Of the 97 records screened, 17 were included. There is strong evidence for lower levels of ADAM10 in platelets of persons with AD compared to cognitively healthy participants. On the other hand, higher levels of ADAM10 were found in plasma. Regarding CSF, controversial results were found with lower and higher levels of ADAM10 in persons with AD compared to healthy older adults. The differences may be due to diverse reasons, including different sample collection and processing and different antibodies, highlighting the importance of standardizing the experiments and choosing the appropriate antibodies for ADAM10 detection. Conclusion Evidence shows that ADAM10 levels are altered in platelets, plasma, serum, and CSF of individuals with AD. The alteration was evident in all stages of the disease, and therefore, the protein may represent a complementary biomarker for the disease. However, more studies must be performed to establish cut-off values for ADAM10 levels to discriminate AD participants from cognitively unimpaired older adults.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Oliveira Monteiro E Pereira de Almeida, M. P., Valle Pedroso, R., Mantellatto Grigoli, M., Vicente Silva, T., Manzine, P. R., & Cominetti, M. R. (2024). ADAM10 as a biomarker for Alzheimer's disease: A systematic review. Revue neurologique. https://doi.org/10.1016/j.neurol.2023.04.002
Vancouver
Oliveira Monteiro E Pereira de Almeida MP, Valle Pedroso R, Mantellatto Grigoli M, Vicente Silva T, Manzine PR, Cominetti MR. ADAM10 as a biomarker for Alzheimer's disease: A systematic review. Revue neurologique. 2024. doi:10.1016/j.neurol.2023.04.002. PMID: 37460331.
BibTeX
@article{oliveiramonteiroepereiradealmeida2024-37460331,
author = {Oliveira Monteiro E Pereira de Almeida, M. P. and Valle Pedroso, R. and Mantellatto Grigoli, M. and Vicente Silva, T. and Manzine, P. R. and Cominetti, M. R.},
title = {{ADAM10 as a biomarker for Alzheimer's disease: A systematic review}},
journal = {Revue neurologique},
year = {2024},
doi = {10.1016/j.neurol.2023.04.002},
pmid = {37460331},
url = {https://doi.org/10.1016/j.neurol.2023.04.002}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background Studies have shown that A Disintegrin and Metalloproteinase 10 (ADAM10) is the main α-secretase in the non-amyloidogenic cleavage of the amyloid precursor protein (APP), avoiding the production of amyloid-β peptide (Aβ), one of the pathological hallmarks of Alzheimer's disease (AD).
- Results Of the 97 records screened, 17 were included.
- There is strong evidence for lower levels of ADAM10 in platelets of persons with AD compared to cognitively healthy participants.
- Regarding CSF, controversial results were found with lower and higher levels of ADAM10 in persons with AD compared to healthy older adults.
Why it matters
This systematic review of 17 studies looked at ADAM10, an enzyme that steers amyloid precursor protein away from making amyloid-β, as a possible Alzheimer's biomarker. ADAM10 was consistently lower in platelets but higher in plasma of people with Alzheimer's, while spinal fluid results conflicted, possibly due to differing lab methods. The authors see it as a possible complementary biomarker but say cut-off values still need to be established.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 53/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Revue neurologique) |
| Journal's citation record | 0 / 4 | Revue Neurologique: journal h-index 70 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 3 / 7 | Cited 24 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Márcia R. Cominetti: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Trinity College Dublin: institution h-index 926 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37460331) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk genes beyond APOE
Also in Risk genes beyond APOE
105 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.